China Pharma Holdings Gross Profit

The latest gross profit for CPHI is $180B as of June 2026. That compares with $-660B in the prior-year period — up 127.1% year over year. That is above the Healthcare sector average of $67B. Investors often review this figure alongside China Pharma Holdings's historical trend and sector peers before judging valuation or financial health.

Over the past year, CPHI's gross profit moved from $-660B to $180B — a 127.1% year-over-year increase. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in China Pharma Holdings's operating scale or balance-sheet position.

Against Healthcare companies, CPHI currently prints $180B for gross profit, while the sector average sits near $67B. That is roughly 165.9% above the sector mean. Large gaps often invite a closer look at China Pharma Holdings's growth, margins, and balance sheet.

A gross profit figure of $180B for CPHI is a snapshot of scale on that line item. On its own it does not say whether the business is healthy — you also want growth rate, margins, and how the number compares with similar companies. The Healthcare average is about $67B. Explore the charts below for those layers of context.

After noting CPHI's gross profit ($180B), review year-over-year change from $-660B, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.